All In Biotech

Drug Trial Radar · NCT07203391

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Dec 1, 2027

Study completion Dec 1, 2029

Sponsor

Lead sponsor
St Vincent's Hospital, SydneyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Conditions

  • Uveal Melanoma, Metastatic

Interventions

  • roginolisibDrug

    Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • To determine the safety and tolerability of roginolisib and tebentafusp in HLA-A*02:01 positive patients advanced uveal melanoma (UM).Time frame: Through study completion, estimated average of 1 year
  2. • To establish a maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of roginolisib and tebentafusp in HLA-A*02:01 positive patients advanced uveal melanoma (UM).Time frame: Through study completion, estimated average of 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • St Vincents Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.